ACAD
32.54
0.00
0.00%
AEMD
5.25
0.00
0.00%
APRI
0.352
0.00
0.00%
ARNA
1.57
0.00
0.00%
ATEC
3.94
0.00
0.00%
CNAT
1.88
0.00
N/A%
CRXM
0.17
0.00
0.00%
CYTX
2.09
0.00
0.00%
DXCM
92.13
0.00
0.00%
GNMK
8.64
0.00
0.00%
HALO
9.88
0.00
N/A%
ILMN
168.99
0.00
N/A%
INNV
0.283
-0.014
-4.714%
INO
9.43
-0.02
-0.21%
ISCO
1.8
0.00
0.00%
ISIS
57.56
0.00
N/A%
LGND
104.305
0.00
0.00%
LPTN
2.54
0.00
0.00%
MBVX
5.01
0.00
0.00%
MEIP
1.9
0.00
0.00%
MNOV
6.08
0.00
0.00%
MRTX
5.23
0.00
0.00%
MSTX
0.429
0.00
0.00%
NBIX
49.17
0.00
0.00%
NUVA
65.47
0.00
0.00%
ONCS
1.72
0.00
0.00%
ONVO
3.85
-0.06
-1.53%
OREX
3.99
0.00
0.00%
OTIC
16.42
0.00
0.00%
QDEL
21.74
0.00
0.00%
RCPT
231.96
0.00
0.00%
RGLS
3.25
0.00
0.00%
RMD
67.19
-0.03
-0.04%
SPHS
3.22
0.00
0.00%
SRNE
6.56
0.00
0.00%
TROV
4.95
0.00
0.00%
VICL
3.85
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
9.33
0.00
0.00%
ACAD
32.54
0.00
0.00%
AEMD
5.25
0.00
0.00%
APRI
0.352
0.00
0.00%
ARNA
1.57
0.00
0.00%
ATEC
3.94
0.00
0.00%
CNAT
1.88
0.00
N/A%
CRXM
0.17
0.00
0.00%
CYTX
2.09
0.00
0.00%
DXCM
92.13
0.00
0.00%
GNMK
8.64
0.00
0.00%
HALO
9.88
0.00
N/A%
ILMN
168.99
0.00
N/A%
INNV
0.283
-0.014
-4.714%
INO
9.43
-0.02
-0.21%
ISCO
1.8
0.00
0.00%
ISIS
57.56
0.00
N/A%
LGND
104.305
0.00
0.00%
LPTN
2.54
0.00
0.00%
MBVX
5.01
0.00
0.00%
MEIP
1.9
0.00
0.00%
MNOV
6.08
0.00
0.00%
MRTX
5.23
0.00
0.00%
MSTX
0.429
0.00
0.00%
NBIX
49.17
0.00
0.00%
NUVA
65.47
0.00
0.00%
ONCS
1.72
0.00
0.00%
ONVO
3.85
-0.06
-1.53%
OREX
3.99
0.00
0.00%
OTIC
16.42
0.00
0.00%
QDEL
21.74
0.00
0.00%
RCPT
231.96
0.00
0.00%
RGLS
3.25
0.00
0.00%
RMD
67.19
-0.03
-0.04%
SPHS
3.22
0.00
0.00%
SRNE
6.56
0.00
0.00%
TROV
4.95
0.00
0.00%
VICL
3.85
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
9.33
0.00
0.00%
Home » Archive by Category

Syndication

SENOMYX ANNOUNCES APPROVAL OF BITTERMYX® BB68 AND SWEETMYX® SR96 FLAVOR INGREDIENTS IN CHINA

August 31, 2016 – 5:30 am

SAN DIEGO, Aug. 31, 2016 /PRNewswire/ — Senomyx, Inc. (NASDAQ: SNMX), a leading company using proprietary taste science technologies to discover, develop and commercialize novel flavor ingredients for the food, beverage and flavor industries, announced today that its flavor ingredients Sweetmyx® SR96 (S9632) and Bittermyx® BB68 (S6821) have been approved for use by the Food and Drug Administration of the People’s Republic of China.  Sweetmyx SR96 is used to boost the sweet taste of products allowing food and beverage companies to significantly reduce sugar while maintaining the same taste to create lower calorie offerings. Bittermyx BB68 is used to reduce the bitterness of certain ingredients and can be used to reduce bitter taste associated with hydrolyzed soy and whey proteins, menthol, caffeine, cocoa, and Rebaudioside A (stevia) for use in food, beverage, OTC and oral care products. 

“We are excited to announce the approval of these flavor ingredients in China,” said John Poyhonen, President and Chief Executive Officer of Senomyx.  “China is a very large market opportunity with a population exceeding 1.3 billion people and retail packaged food and beverage sales of approximately $600 billion annually1,” Poyhonen noted.  “These approvals also further validate our ability to attain approval by major regulatory bodies throughout the world.” 

This regulatory approval allows Senomyx to pursue commercialization of these flavor ingredients in China in a wide range of foods and beverages.  These ingredients are available to flavor houses through Senomyx’s direct sales Complimyx® line and can also be commercialized by two Senomyx collaborators in certain product categories. 

About Senomyx, Inc. (www.senomyx.com)
Senomyx discovers novel flavor ingredients and natural high intensity sweeteners that allow food and beverage companies to create better-for-you products.  Under its direct sales program, Senomyx sells its Complimyx® brand flavor ingredients, Sweetmyx®, Savorymyx®, and Bittermyx®, to flavor companies for use in a wide variety of foods and beverages.  In addition, Senomyx has partnerships with leading global food, beverage, and ingredient supply companies, which are currently marketing products that contain Senomyx’s flavor ingredients.  For more information, please visit www.senomyx.com.

Forward-Looking Statements

Statements in this communication that are “forward-looking statements” are based on currently available information, operating plans and projections about future events and trends. They inherently involve risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements. Such forward looking statements include, but are not limited to, the potential to use SR96, the Sweetmyx flavor ingredient, to restore the original taste profile in foods and beverages in which sucrose has been reduced; and BB68, the Bittermyx flavor ingredient, to block the bitterness of certain products, and the anticipated timing of consumer acceptance. Risks associated with those forward-looking statements include the fact that the cost to manufacture and/or formulate the Sweetmyx and Bittermyx ingredients into packaged food and beverage products may be higher than anticipated, which could discourage market acceptance; commercial quantities of the Sweetmyx and Bittermyx ingredients may not be available when currently anticipated; we may encounter unexpected difficulties using the new Sweetmyx and Bittermyx flavor ingredients to manufacture food or beverage products at commercial scale; the launch of any new or reformulated commercial product is subject to inherent uncertainty and potential delay; consumer acceptance testing may take longer than anticipated or may not be successful; Senomyx may be asked to complete additional studies to evaluate and/or monitor the safety of new flavor ingredients in order to maintain applicable regulatory approvals and/or obtain regulatory approvals in other geographies; Senomyx or its collaborators may be unable to obtain and maintain the regulatory approval of these ingredients in China and elsewhere; Senomyx’s ability to compete in the flavor ingredients market may decline if Senomyx does not adequately protect its proprietary technologies; and the reference to the estimated potential market opportunity for retail packaged food and beverage sales in China is made by Euromonitor© and does not represent Senomyx’s forecast or prediction.  These and other risks and uncertainties are described more fully in Senomyx’s most recently filed SEC documents, including its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K under the headings “Risks Related to Our Business” and “Risks Related to Our Industry.” All forward-looking statements contained in this press release speak only as of the date on which they were made. Senomyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:  
Megan Knight            
Senomyx, Inc.
Investor Relations & Corporate Communications
858-646-8430
megan.knight@senomyx.com

1 Source © Euromonitor International 2016

 

SOURCE Senomyx, Inc.

Zavante Therapeutics Forms Scientific Advisory Board And Appoints Infectious Disease Experts As Members

August 31, 2016 – 5:00 am

Scientific Advisory Board members to support pre-clinical, microbiology and clinical development programs for lead product candidate ZTI-01

SAN DIEGO, Aug. 31, 2016 /PRNewswire/ — Zavante Therapeutics, Inc., a privately-held, late clinical-stage biopharmaceutical company, today announced that it has formed a Scientific Advisory Board and has appointed eight infectious disease specialists to serve as strategic and scientific resources to the Company.  ZTI-01 (fosfomycin for injection) is an investigational antibiotic under development for the treatment of hospitalized patients with complicated urinary tract infections (cUTI), including acute pyelonephritis. 

“We are pleased to bring together this strong team of infectious disease specialists to support the development efforts of ZTI-01, our lead product candidate,” said Ted Schroeder, chief executive officer of Zavante. “We believe ZTI-01, a first-in-class injectable antibiotic, will provide additional treatment options in the hospital setting where current therapeutic choices are severely limited.”  

Inaugural members of the Zavante Scientific Advisory Board:

For a full biography of each advisory board member, please visit www.zavante.com/sab.

Zavante’s ZTI-01, is a first-in-class injectable antibiotic that has demonstrated a broad spectrum of bactericidal Gram-negative and Gram-positive activity in vitro, including activity against most contemporary multi-drug resistant (MDR) strains.

FDA granted Fast Track designation and Qualified Infectious Disease Product (QIDP) designation for the investigation of ZTI-01 for the following indications:

    • cUTI
    • Hospital-Acquired Bacterial Pneumonia (HABP)
    • Ventilator-Associated Bacterial Pneumonia (VABP)
    • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    • Complicated Intra-Abdominal Infections (cIAI)

In July 2016, the first patient was randomized in the ZEUS (ZTI-01 Efficacy and Safety) study.  ZEUS is the pivotal study intended to support a New Drug Application for ZTI-01 in the U.S. The study is titled “Multi-center, randomized, double-blind, comparative study to evaluate the safety and efficacy of ZTI-01 vs. piperacillin/tazobactam in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults.” More clinical trial information is available at www.clinicaltrials.gov.

The Company expects to complete enrollment in the ZEUS study in the first half of 2017.

About Zavante Therapeutics, Inc.

Zavante Therapeutics, Inc. is a privately-held, late clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.

Additional information is available at www.zavante.com

Logo – http://photos.prnewswire.com/prnh/20151215/296383LOGO

SOURCE Zavante Therapeutics, Inc.

MabVax Therapeutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference

August 31, 2016 – 5:00 am

SAN DIEGO, Aug. 31, 2016 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (NasdaqCM: MBVX), a clinical-stage oncology drug development company, announced today that it will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference being held September 11-13, 2016 at the Lotte New York Palace Hotel, New York City.

Event: Rodman & Renshaw 18th Annual Global Investment Conference
Location: Lotte New York Palace Hotel
Date: Tuesday, September 13, 2016
Time: 2:10 PM (EDT) in Holmes II Room (4th Floor)

MabVax Therapeutics President and CEO David Hansen will deliver the Company’s presentation and discuss recent business highlights, as well as upcoming milestones related to its phase 1 clinical trials of MVT-5873 for the treatment of pancreatic cancer and MVT-2163 as a companion diagnostic. Mr. Hansen will also be available for one-on-one meetings. To arrange a meeting with management, please contact Robert Haag at mbvx@irthcommunications.com or visit this link to schedule a one-on-one directly. 

About Rodman & Renshaw Conferences, LLC  

The Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, is being held on September 11 – 13, 2016 at the Lotte New York Palace Hotel in New York City. Approximately 300 companies will be presenting their businesses to an audience of approximately 2,000 attendees.  The conference will focus on tracks dedicated to Healthcare; Natural Resources; Technology; Media and telecommunications; and Cleantech. This year’s conference will bring growth companies together with a vast audience and strategic investors. In addition to corporate presentations, Rodman facilitates one-on-one investor meetings and provides platforms for engaged Q&A sessions and daily networking opportunities.  

About MabVax

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the Company’s proprietary vaccines.  MabVax’s HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center, or MSK.  In preclinical research, the 5B1 antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers.  The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer.  MabVax’s two lead antibody clinical programs, currently in Phase I clinical trials, utilize HuMab-5B1 as a naked antibody (MVT-5873) and as an immuno-PET imaging agent (MVT-2163).  Additional information is available at www.mabvax.com.

Forward Looking Statements:

This press release contains “forward-looking statements” regarding matters that are not historical facts, including statements relating to the Company’s clinical trials and product development pipeline.  We have no assurance that all of the product development pipeline will be fully developed by the Company.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the fiscal year ended December 31, 2015, as amended and supplemented from time to time and the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov.  The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Investor Contact:

Robert Haag
Managing Director
IRTH Communications
MBVX@irthcommunications.com
1-866-976-4784

 

SOURCE MabVax Therapeutics Holdings, Inc.

MabVax Therapeutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference

August 31, 2016 – 5:00 am

SAN DIEGO, Aug. 31, 2016 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (NasdaqCM: MBVX), a clinical-stage oncology drug development company, announced today that it will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference being held September 11-13, 2016 at the Lotte New York Palace Hotel, New York City.

Event: Rodman & Renshaw 18th Annual Global Investment Conference
Location: Lotte New York Palace Hotel
Date: Tuesday, September 13, 2016
Time: 2:10 PM (EDT) in Holmes II Room (4th Floor)

MabVax Therapeutics President and CEO David Hansen will deliver the Company’s presentation and discuss recent business highlights, as well as upcoming milestones related to its phase 1 clinical trials of MVT-5873 for the treatment of pancreatic cancer and MVT-2163 as a companion diagnostic. Mr. Hansen will also be available for one-on-one meetings. To arrange a meeting with management, please contact Robert Haag at mbvx@irthcommunications.com or visit this link to schedule a one-on-one directly. 

About Rodman & Renshaw Conferences, LLC  

The Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, is being held on September 11 – 13, 2016 at the Lotte New York Palace Hotel in New York City. Approximately 300 companies will be presenting their businesses to an audience of approximately 2,000 attendees.  The conference will focus on tracks dedicated to Healthcare; Natural Resources; Technology; Media and telecommunications; and Cleantech. This year’s conference will bring growth companies together with a vast audience and strategic investors. In addition to corporate presentations, Rodman facilitates one-on-one investor meetings and provides platforms for engaged Q&A sessions and daily networking opportunities.  

About MabVax

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the Company’s proprietary vaccines.  MabVax’s HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center, or MSK.  In preclinical research, the 5B1 antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers.  The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer.  MabVax’s two lead antibody clinical programs, currently in Phase I clinical trials, utilize HuMab-5B1 as a naked antibody (MVT-5873) and as an immuno-PET imaging agent (MVT-2163).  Additional information is available at www.mabvax.com.

Forward Looking Statements:

This press release contains “forward-looking statements” regarding matters that are not historical facts, including statements relating to the Company’s clinical trials and product development pipeline.  We have no assurance that all of the product development pipeline will be fully developed by the Company.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the fiscal year ended December 31, 2015, as amended and supplemented from time to time and the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov.  The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Investor Contact:

Robert Haag
Managing Director
IRTH Communications
MBVX@irthcommunications.com
1-866-976-4784

 

SOURCE MabVax Therapeutics Holdings, Inc.

Technical Support Specialist – BioPhase Solutions – San Diego, CA

August 31, 2016 – 3:05 am

We are currently looking for a Technical Support Specialist to work for a leading San Diego biotechnology company….From BioPhase Solutions – Wed, 31 Aug 2016 10:05:29 GMT – View all San Diego jobs

Research Analyst I – Informa Business Intelligence – San Diego, CA

August 31, 2016 – 12:36 am

Informa’s Business Intelligence (BI) division, part of the FTSE 100 Informa Group, provides specialist data, intelligence and insight to our customers, helping…
From Informa Business Intelligence – Wed, 31 Aug 2016 07:36:09 GMT – View all San Diego jobs

Senior Patent Agent – Takeda Pharmaceuticals – San Diego, CA

August 30, 2016 – 9:54 pm

Background in biotechnology or organic chemistry is preferred. The individual is to perform patent services for the organization in areas relevant to the…From Takeda Pharmaceuticals – Wed, 31 Aug 2016 04:54:42 GMT – View all San Diego jobs

Manager, Technical Support – Illumina, Inc. – San Diego, CA

August 30, 2016 – 9:04 pm

3-5 years of Support Management experience, biotech experience preferred. This position is responsible for the leadership and continuous development of a team…From Illumina, Inc. – Wed, 31 Aug 2016 04:04:25 GMT – View all San Diego jobs

Director, Quality Assurance & Regulatory Affairs – Ajinomoto Althea, Inc. – San Diego, CA

August 30, 2016 – 8:06 pm

Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…From Ajinomoto Althea, Inc. – Wed, 31 Aug 2016 03:06:54 GMT – View all San Diego jobs

Clinical Research Associate (San Diego, CA)

August 30, 2016 – 2:05 pm

SUMMARY OF ESSENTIAL DUTIES AND RESPONSIBILITIES
The primary function in this position will be to provide departmental support in the area of Clinical Affairs, including:
Transfer/enter data from clinical study Case Report Forms (CRFs) into REVA’s […